Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction.Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of 2,500,000…
Ascendis Pharma’s $400 Million ADSs Public Offering
